Clicky

Zealand Pharma A/S(ZEAL)

Description: Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.


Keywords: Biotechnology Diabetes Peptides Boehringer Ingelheim Hypoglycemia Short Bowel Syndrome Congenital Hyperinsulinism Lixisenatide Bariatric Surgery Gastrointestinal And Metabolic Diseases Glp 2 Severe Hypoglycemia Treatment Of Short Bowel Syndrome

Home Page: www.zealandpharma.com

Sydmarken 11
Copenhagen, 2860
Denmark
Phone: 45 88 77 36 00


Officers

Name Title
Mr. Adam Sinding Steensberg M.D. Pres & CEO
Ms. Henriette Wennicke Chief Financial Officer
Mr. Ivan Mourits Moller Chief Operating Officer
Lani Pollworth Morvan Investor Relations & Communications Officer
Mr. Mads Kronborg Head of Investor Relations & Communication
Mr. Ravinder Chahil Sr. VP & Gen. Counsel
Ms. Christina Sonnenborg Bredal Sr. VP and Global Head of People & Organization
Ms. Hanne Heidenheim Bak Sr. Project Director, R&D Operations Mang. and Employee Representative Director
Dr. Jens Damsgaard Mikkelsen M.D. Head of Molecular Pharmacology
Dr. Danilo Verge Head of Global Medical Affairs

Exchange: CO

Country: DK

Currency: Danish krone (kr)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 27.7732
Price-to-Sales TTM: 36.7281
IPO Date:
Fiscal Year End: December
Full Time Employees: 203
Back to stocks